INVESTMENT IN EQUITY SECURITIES, AT FAIR VALUE AND LONG-TERM INVESTMENTS - BioInvent International AB - Summary of Investments (Details) $ in Thousands |
12 Months Ended |
|---|---|
|
Dec. 31, 2024
USD ($)
| |
| Schedule of Investments | |
| Cost | $ 3,379 |
| Gross unrealized losses | (756) |
| Equity securities at fair value | 2,623 |
| Common Stock | BioInvent International AB | |
| Schedule of Investments | |
| Cost | 2,723 |
| Gross unrealized losses | (166) |
| Equity securities at fair value | 2,557 |
| Warrants | BioInvent International AB | |
| Schedule of Investments | |
| Cost | 656 |
| Gross unrealized losses | (590) |
| Equity securities at fair value | $ 66 |
| X | ||||||||||
- Definition Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI). Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Cost of the investment. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|